Cashu
ImmunityBio Completes Patient Enrollment in Bladder Cancer Immunotherapy Trial with Anktiva and BCG
4 days ago
Stocks
Health Care
ibrx
ImmunityBio
NASDAQ: IBRX
-0.97 (-9.70%)
9.03
USD
At close at Mar 04, 21:39 UTC
Latest ImmunityBio News
benzinga.com
ImmunityBio Investors Rally Behind Cancer Trial Milestone
7 days ago
benzinga.com
ImmunityBio Supersedes Expectations With Fivefold Revenue Increase
7 days ago
benzinga.com
ImmunityBio's 471% Stock Rally Could Enter Next Round If Shorts Capitulate
8 days ago
prnewswire.com
Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026
8 days ago
benzinga.com
ImmunityBio Explodes To Near 52-Week High As Bladder Cancer Drug Anktiva Drives Massive 700% Revenue Growth
9 days ago
benzinga.com
ImmunityBio Posts Upbeat Q4 Earnings, Joins Arcellx, Vanda Pharmaceuticals And Other Big Stocks Moving Higher On Monday
10 days ago
benzinga.com
Earnings Breakdown: ImmunityBio Q4
10 days ago
benzinga.com
ImmunityBio Taps 85-Person Sales Team to Launch Its Bladder Cancer Drug In European Countries
13 days ago
benzinga.com
ImmunityBio Holds Golden Cross As Stock Trades 170% Above 200-Day Average
14 days ago
benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
15 days ago
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.